Lyell Immunopharma (LYEL) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$2.13.
- Lyell Immunopharma's EPS (Weighted Average and Diluted) rose 3879.31% to -$2.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.32, marking a year-over-year increase of 17083.89%. This contributed to the annual value of -$1.28 for FY2024, which is 3763.14% down from last year.
- Latest data reveals that Lyell Immunopharma reported EPS (Weighted Average and Diluted) of -$2.13 as of Q3 2025, which was up 3879.31% from -$2.89 recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q4 2022 and a low of -$3.59 during Q2 2024
- Its 5-year average for EPS (Weighted Average and Diluted) is -$1.05, with a median of -$0.27 in 2023.
- Per our database at Business Quant, Lyell Immunopharma's EPS (Weighted Average and Diluted) surged by 9386.57% in 2021 and then crashed by 164000.0% in 2024.
- Lyell Immunopharma's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.18 in 2021, then surged by 83.33% to -$0.03 in 2022, then crashed by 566.67% to -$0.2 in 2023, then crashed by 275.22% to -$0.75 in 2024, then tumbled by 183.83% to -$2.13 in 2025.
- Its EPS (Weighted Average and Diluted) was -$2.13 in Q3 2025, compared to -$2.89 in Q2 2025 and -$0.18 in Q1 2025.